Your investment options
At Craigs we provide you with the flexibility to build a portfolio of investments from our list of investment options.
We have over 250 investment options available for you to invest in. Our investment options include a range of equity, fixed interest, investment trusts, NZ managed funds, index funds and listed property trust investments, available on local and international listed and unlisted markets.
If you would like to review and make changes to your portfolio please contact your Craigs investment adviser or our Client Services team.
Read our research insights on three of our current investment options below.
ASML Holding N.V.
ASML.NASDAQ | Technology
Our Classification: Core
Risk indicator: 7/7
Sustainability score: To be assessed
About ASML
ASML is the top provider of machines that print circuits in computer chips. More technically, ASML is the leading supplier of lithography systems (machines that print circuits) used in semiconductor production (used to create computer chips). The company provides hardware, software and services solutions to its customers.
What makes ASML different?
ASML has revolutionised chipmaking with its advanced lithography technologies, enabling the semiconductor industry to produce significantly more complex and powerful chips. The company’s pioneering work in extreme ultraviolet (EUV) lithography has been particularly transformative, solidifying its dominant position in the lithography market. ASML now commands over 80% market share, up from 55% a decade ago. Lithography serves as the primary bottleneck in chip production. The performance and capabilities of ASML’s systems directly influence the quality and efficiency of the entire semiconductor manufacturing process. As chip technology advances, the demand for more sophisticated lithography solutions continues to grow, further reinforcing ASML’s critical role in the semiconductor value chain. ASML’s competitive moats include technological superiority, scale advantages, and high switching costs, which translate into pricing power and expanding service revenue potential.
Opportunities and threats
The semiconductor industry is poised for long-term structural growth, fuelled by the ongoing digital transformation and accelerated by the rise of generative artificial intelligence (AI). This marks the fourth major era of computing, with the growing demand for advanced chips spurring increased equipment spending by semiconductor manufacturers. Additionally, intensifying competition among chip designers and the onshoring of semiconductor manufacturing provide further tailwinds for ASML’s growth prospects. ASML has a strong track record of outperforming its longer-term financial targets. The company has close relationships with its customers to ensure its technology meets the specific needs of their manufacturing processes. This partnership model, combined with long development cycles, provides ASML with good visibility into future demand for its systems.
Our view and outlook
ASML is the dominant supplier of lithography systems to the global semiconductor industry. The company maintains a significant technology lead over its competitors, supported by strategic partnerships and large investments in research and development. We expect ASML to outperform the structurally growing semiconductor market due to increased adoption of its next-generation systems and the company’s pricing power. ASML stands to benefit from several secular growth trends supporting double-digit earnings growth in the coming years.
First Trust NASDAQ Cybersecurity ETF
CIBR.NASDAQ | Technology
Our Classification: Supplementary
Risk indicator: 6/7
Sustainability score: Funds are not assessed
About CIBR
CIBR provides a diversified exposure to the core players within the cybersecurity sector.
CIBR is an exchange-traded fund that tracks the performance of the Nasdaq CTA Cybersecurity Index. The Nasdaq CTA Cybersecurity Index represents companies engaged in providing cybersecurity services. It includes companies primarily involved in the building, implementation and management of security protocols applied to private and public networks, computers and mobile devices in order to provide protection of the integrity of data and network operations.
What makes CIBR different?
Our increasing dependence on the internet, digital devices and vast corporate networks provides key challenges in securing essential data, intellectual property and personal information. Cybersecurity is the use of technologies and controls aimed at protecting business systems, networks, programmes, devices and data from cyberattacks. Cyber criminals and cyberattacks are becoming more sophisticated, with attacks evolving in their complexity as they increasingly deploy artificial intelligence. Today, the average cyberattack is not coming from a person sitting behind a keyboard but from an artificial intelligence algorithm running on a super-computer 24 hours per day and seven days a week. It attacks every IP address it can find (both large and small enterprises and individuals) and the impact and cost are increasing.
Opportunities and threats
Businesses are increasingly viewing cybersecurity as a mission critical function given the significant business and reputational risk associated with a security breach. The need for leading-edge protection against cyberattacks is aimed at preventing theft of intellectual property, financial data and assets as well as protecting brand equity through reduced reputational risk. The View from the Board of Directors Survey (2022) conducted by Gartner found that 88% of respondents viewed cybersecurity risk as a business risk and not just a technology risk, with over half of respondents having experienced a cybersecurity risk incident in the previous two years. Furthermore, an increasing number are now responding to the threats by instituting cybersecurity board committees that report to a dedicated board member. In 2004, the global cybersecurity market was worth approximately US$3.5bn. By 2020, that had grown to US$125bn according to global market intelligence firm, IDC, and is projected to be over US$200bn by 2025 representing an industry growth rate of approximately 9% per annum.
Our view and outlook
CIBR provides a cost-efficient way for investors to own a collection of companies in the cybersecurity industry. CIBR is the largest cybersecurity ETF and offers the best liquidity. Although the fund’s concentrated positioning within the cybersecurity sector makes it less diversified than its key peers (it has historically been more volatile as a consequence), we believe it provides a more pure exposure to the core players in cybersecurity.
Telix Pharmaceuticals Limited
TLX.ASX | Healthcare
Our Classification: Niche
Risk indicator: 7/7
Sustainability score: To be assessed
About TLX
TLX is a leader in cancer radiopharmaceuticals (radioactive medicines used to diagnose or treat diseases) and is currently expanding its diagnostics and therapeutics portfolio with a focus on self-sufficient manufacturing.
TLX aims to commercialise radiopharmaceutical assets, traditionally a cottage industry within hospital nuclear medicine departments. TLX’s first commercial product, a prostate cancer diagnostic launched in 2022, has exceeded expectations and highlighted the potential of radiopharmaceuticals in oncology. TLX’s business is divided into diagnostics and therapeutics. Its diagnostic is a radiopharmaceutical used in PET scans to detect cancer cells more accurately. This advanced imaging technique helps doctors identify tumours and assist in determining the best treatment plan. While therapeutics are still in development, diagnostics have shown significant market growth. The prostate cancer diagnostic continues to perform strongly, with two additional diagnostics, targeting kidney and brain cancer, expected to receive approval by year end.
What makes TLX different?
Over the past year, TLX has expanded its infrastructure and manufacturing capacity, reducing reliance on outsourcing through smart manufacturing acquisitions. As radiopharmaceuticals are perishable (‘melting ice cubes’), internalising production reduces costs and logistical challenges. Its large Belgium facility differentiates it from many peers as an infrastructure-heavy company, essential for efficiently managing the radiopharmaceutical supply chain. TLX has completed an acquisition to strengthen its direct commercialisation capabilities in the U.S. The added infrastructure provides greater control over the production and distribution of its diagnostic products, while also positioning the company for future therapeutic development and manufacturing.
Opportunities and threats
TLX’s upcoming prostate cancer therapy Phase 3 trial has an interim readout expected for mid-2025. If highly positive, this could accelerate approval timelines. However, full approval is still likely three years away. Recent pilot study results have boosted confidence, but if the interim data is negative, it could impact future growth. TLX plans to have two additional diagnostics on the market soon, contributing to significant revenue and reducing reliance on a single product. Its kidney cancer diagnostic, expected to launch this year, could drive substantial positive momentum.
Our view and outlook
TLX has one approved diagnostic (for prostate cancer), which launched two years ago and has seen tremendous growth. The business has established a significant commercial footprint in the US, as well as enhanced its in-house manufacturing and development capabilities, providing an advantage given the perishable nature of radiopharmaceuticals. With two more diagnostics expected to be on the market soon, its diversified portfolio and growth trajectory make TLX a strong contender in the market. While its therapeutics are still in development, this segment presents a much larger opportunity than diagnostics, offering potential for significant market growth. The company joined the ASX 100 in July 2024, cementing its position as a leading business. Inclusion in this index enhances its profile and adds to investor interest.
About risk indicators and sustainability scores
Risk indicators are assessed by Craigs Investment Strategy Group and are rated from 1 (low) to 7 (high). The rating reflects how much the value of the company goes up and down (volatility). A higher risk generally means there is the potential for higher returns over time, but with the risk of higher losses, and there are likely to be more ups and downs along the way. To help you clarify your own attitude to risk, work out your risk profile at craigsip.com/risk-profiler or speak to your Investment Adviser.
Sustainability scores are assessed by Craigs Investment Strategy Group sustainability team and are calculated as an average rating out of five for environmental, social and governance factors. An N/A sustainability score means a sustainability assessment has not been made. For further information on how we calculate these scores, please refer to this report or speak to your Investment Adviser.